

GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in thousands, except per share amounts)

Below is a reconciliation of Gilead's GAAP operating results and diluted per share amounts as reported in the attached press release dated October 16, 2008. Non-GAAP net income and net income per diluted share for the three months ended September 30, 2008 and 2007, and the nine months ended September 30, 2007, are presented excluding the after-tax impact of stock-based compensation expense and the related methodology for computing dilutive securities for net income per diluted share purposes. Non-GAAP net income and net income per diluted share for the nine months ended September 30, 2008 is presented excluding the after-tax impact of the purchased in-process research and development expense incurred in connection with the acquisition of all of Navitas Assets, LLC's assets related to its cicletanine business, as well as the after-tax impact of stock-based compensation expense and the related methodology for computing dilutive securities for net income per diluted share purposes. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under GAAP.

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|-------------------|------------------------------------|---------------------|
| | 2008 | 2007 | 2008 | 2007 |
| Net income (GAAP) | \$ 504,005 | \$ 398,319 | \$ 1,442,960 | \$ 1,213,656 |
| Stock-based compensation expense, net of tax | 30,081 | 31,777 | 82,491 | 106,223 |
| Purchased in-process research and development expense, net of tax | - | - | 7,769 | - |
| Net income (Non-GAAP) | <u>\$ 534,086</u> | <u>\$ 430,096</u> | <u>\$ 1,533,220</u> | <u>\$ 1,319,879</u> |
| Shares used in per share calculation - diluted (GAAP) | 960,585 | 959,043 | 964,267 | 962,804 |
| Dilutive securities | 1,924 | 1,780 | 2,103 | 2,108 |
| Shares used in per share calculation - diluted (Non-GAAP) | <u>962,509</u> | <u>960,823</u> | <u>966,370</u> | <u>964,912</u> |
| Net income per share - diluted (GAAP) | <u>\$ 0.52</u> | <u>\$ 0.42</u> | <u>\$ 1.50</u> | <u>\$ 1.26</u> |
| Net income per share - diluted (Non-GAAP) | <u>\$ 0.55</u> | <u>\$ 0.45</u> | <u>\$ 1.59</u> | <u>\$ 1.37</u> |